Monday, July 15, 2024
Mitochondrial Health

Mechanism-based Off-target Screening De-risks Clinical Development of Antiviral Nucleoside/tide…



Presented By: Joy Feng, PhD

Speaker Biography: Joy Feng is a Principal Scientist at Gilead Sciences, Inc. She has a Ph.D. degree in Medicinal Chemistry from the University of Florida. During her postdoc training at Dr. Karen Anderson’s lab at Yale, Joy developed her deep appreciation of mitochondria while studying drug-induced mitochondrial toxicity using an enzymatic approach.

Webinar: Mechanism-based Off-target Screening De-risks Clinical Development of Antiviral Nucleoside/tide Drugs

Webinar Abstract: Nucleoside/tide analogs have played a key role in the treatment of viral infections caused by DNA viruses such as herpes virus and hepatitis B virus, as well as RNA viruses such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza virus, and most recently the coronavirus SARS-CoV-2, the pathogen causing the COVID-19 pandemic.

source

Similar Posts